Fusion Antibodies PLC Posting of Annual Report and Notice of AGM (8400Y)

TIDMFAB

RNS Number : 8400Y

Fusion Antibodies PLC

28 August 2018

Fusion Antibodies plc

("Fusion" or the "Company")

Posting of Annual Report and Notice of AGM

Fusion Antibodies plc (AIM: FAB), a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, confirms that the Annual Report and Accounts for the year ended 31 March 2018 ('2018 Annual Report and Accounts'), the Notice of Annual General Meeting ('AGM') and a Form of Proxy will be posted to shareholders today.

The AGM will be held on 21 September 2018 at 11am at Mooney Lounge, Wellington Park Hotel, 21 Malone Road, Belfast, BT9 6RU.

A copy of the 2018 Annual Report and Accounts and Notice of AGM is available to download from the Company website, www.fusionantibodies.com.

Enquiries:

 
 Fusion Antibodies plc                                     www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                              Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                   Tel: [phone] 
 Virginia Bull / James Reeve / Asha Chotai 
 
 Walbrook PR                      Tel: [phone] or [e-mail] 
 Paul McManus                                              Mob: [phone] 
 Anna Dunphy                                               Mob: [phone] 
 
 

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx(TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base, which includes eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011. The Company has a highly experienced management team with a combined 47 years' experience in the biopharma industry.

The global monoclonal antibody therapeutics market, which accounted for 43 per cent. of the global biologics market in 2016, was valued at between $85.4 billion and $86.7 billion in 2015 and is forecast to increase at a CAGR of between 8.2 per cent. and 12.2 per cent. for the period 2016 to 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

ACSEAEPLAFNPEFF

(END) Dow Jones Newswires

August 28, 2018 02:00 ET (06:00 GMT)